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A patient was referred for radiotherapy of histologicallyconfirmed squamous cell carcinoma in the left upper lobe
and a subcarinal lymph node, stage IIIA (T3N2M0). He tested
human immunodeficiency virus-positive 16 years before (cur-
rent CD4 count of 58 cells/L). His antiretroviral regimen
included 1250 mg nelfinavir every 12 hours and five other
antiretrovirals. After extensive discussion regarding chemora-
diotherapy versus radiation therapy alone, he declined chemo-
therapy. From his own review of the preclinical literature on
nelfinavir as a radiosensitizer, he chose to discontinue his antiretro-
viral regimen and take nelfinavir alone at 3750 mg every 12 hours.
Treatment planning positron emission tomography-
computed tomography revealed a 5.4  3.4  4.0 cm
primary tumor with a 1.6  0.5  2.2 cm central necrotic
cavity (Figure 1A). Intensity-modulated radiation therapy was
planned to 74 Gy total in 37 daily fractions (Figure 1B).
Radiotherapy began 5 days after increasing the nelfinavir
dose. The patient received nine treatments (18 Gy) without
toxicity. Positron emission tomography-computed tomogra-
phy for adaptive replanning revealed primary tumor size
decrease to 4.6  3.9  3.9 cm and maximum standardized
uptake value decrease from 11 to 5.8. The central cavity now
measured 2.7 1.7 2.2 cm and communicated with the left
bronchus (Figure 1C). On that day, he experienced mild
hemoptysis not requiring intervention. He received one more
fraction on the following day, completing 20 Gy, after which
he suffered fatal massive hemoptysis.
Autopsy indicated hemorrhage into the left lower lung
parenchyma. Gross examination identified no residual sub-
carinal node or primary tumor, which was replaced by a 7 
4  4 cm cavity containing necrotic debris. A 1.5  1.5 cm
erosion tracked from the cavity into the left main bronchus
(Figure 2C). Histology revealed microscopic foci of squa-
mous cell carcinoma with extensive necrosis around the
cavity and in the erosion track (Figure 2B). The adjacent lung
parenchyma, bronchial mucosa, blood vessels, and nerves
lacked histologic evidence of radiation injury. Thus, it appeared
that rapid tumor regression allowed bleeding through the erosion
into the lung parenchyma, leading to asphyxiation.
DISCUSSION
After 20 Gy radiation without concurrent chemother-
apy, our patient exhibited complete response grossly with
only microscopic residual disease. In the landmark Intergroup
0139 trial for stage IIIA non-small cell lung cancer, only 14%
of subjects achieved complete pathologic responses despite
45 Gy and concurrent chemotherapy.1 Although an imperfect
comparison, this highlights that marked early responses are
uncommon even with more intensive therapy and that we may
have observed tumor-specific radiosensitization by nelfinavir.
Preclinically, nelfinavir demonstrated tumor-specific
radiosensitization through downregulation of the phosphati-
dylinositol 3-kinase (PI3K)-Akt pathway.2,3 Tumor hypoxia
is an important radioresistance mechanism,4 and PI3K-Akt
inhibition increases tumor oxygenation through antiangio-
genic “normalization” of vasculature.5,6
Nelfinavir is well tolerated in patients with acquired im-
mune deficiency syndrome, and at the common dose of 1250 mg
every 12 hours, clinically relevant PI3K-Akt inhibition is mea-
sured.2 For these reasons, nelfinavir was studied in a recent
phase I trial for pancreatic cancer, showing promising activity as
a radiosensitizer.3 Toxicities were not observed in a case series
that included three patients treated with thoracic radiation and
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nelfinavir.2 However, hemoptysis has been described with an-
other antiangiogenic drug, bevacizumab, when treating lung
tumors with cavitation,7 and given our experience with this
patient, we recommend using nelfinavir with thoracic ra-
FIGURE 2. A, Endobronchial biopsy showing invasive squamous
cell carcinoma. Scale bar 50 m. B, Postmortem histology. Micro-
scopic section of lung tumor from the necrotic cavity. Extensive
tumor necrosis and microscopic residual squamous cell carcinoma
(arrow) with radiation-induced changes (arrowhead) are seen.
Scale bar 50 m. C, Left lung at autopsy. A 7  4  4 cm ne-
crotic cavity is present at the hilum. A probe is passed from the
main bronchus into the cavity through a 1.5  1.5 cm erosion.
FIGURE 1. A, Pretreatment axial positron emission tomog-
raphy-computed tomography (PET-CT) image showing the
hypermetabolic left upper lung tumor (arrow) and subcarinal
lymph node (arrowhead). B, Axial CT image with dose distri-
bution (at or above the prescription dose) superimposed.
The maximum point dose is 84.5 Gy and is located in the
subcarinal lymph node target. A small area of cavitation is
already present before starting radiation. C, Axial CT image
after nine fractions (18 Gy) of intensity-modulated radiation
therapy (IMRT), demonstrating decrease in tumor size, and
enlargement of an area of central cavitation tracking into the
left main bronchus (arrow).
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diation only in clinical trials until the optimal use of this
promising combination has been elucidated.
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